Prostate Cancer Center
The UCSF Prostate Cancer Center provides comprehensive, cutting-edge care to patients with prostate cancer as well as men at high risk of developing the condition. With an emphasis on early screening and detection, our center offers a range of services, from active surveillance for low-risk cancers to the latest techniques for cancers at all stages, whether localized (confined to the prostate gland) or advanced (spread to tissues beyond the pelvis). UCSF is a major research center for later-stage prostate cancer and offers the best treatments available.
We also connect patients with integrative medicine services (in which experts combine complementary therapies with mainstream treatments), nutrition and lifestyle counseling, support groups and educational resources. Our mission is to optimize our patients' quality of life during treatment and beyond.
Our team of experts includes urologic cancer surgeons, radiation oncologists, medical oncologists and other subspecialists. In addition to caring for patients, our doctors are at the forefront of prostate cancer research and strive to quickly translate new findings into more effective methods of prevention, diagnosis and treatment.
Patient Conference on Prostate Cancer
Co-hosted by the UCSF Helen Diller Family Comprehensive Cancer Center and the California Prostate Cancer Coalition, this annual conference provides an outstanding opportunity to hear the latest on prostate cancer care from leading experts. Explore videos from recent conferences that can help you make informed decisions around monitoring, treatment and more.
Dealing with treatment side effects
Patient education
Rankings & achievements
-
Among the top hospitals in the nation
-
Best in Northern California and No. 7 in the nation for cancer care
-
Best in Northern California for urology
-
in NIH funding for urology research
-
Designated comprehensive cancer center
-
Commission on Cancer accredited program
-
A founding member of this alliance of the world’s top cancer centers
-
Rated high-performing hospital for prostate cancer surgery
Care providers
-
Peter Carroll
MD, MPH
Urologic oncologist -
Matthew Cooperberg
MD, MPH
Urologic oncologist -
Laura Crocitto
MD
Urologic oncologist -
Maxwell V. Meng
MD
Urologic oncologist -
Hao Nguyen
MD, PhD
Urologic oncologist -
Anobel Odisho
MD, MPH
Urologic oncologist -
Sima Porten
MD, MPH
Urologic oncologist -
Katsuto Shinohara
MD
Urologic oncologist -
Samuel L. Washington III
MD, MAS
Urologic oncologist -
Krisztina Emodi
FNP, MPH, CNS
Nurse practitioner -
Sian Mara
PA
Physician assistant -
Sara McRorey
PA-C
Physician assistant -
Tia Briana Watson
NP, MSN
Nurse practitioner
-
Rahul Aggarwal
MD
Genitourinary oncologist -
Hala Borno
MD
Medical oncologist -
Rohit Bose
MD, PhD
Genitourinary oncologist -
Jonathan Chou
MD, PhD
Genitourinary oncologist -
Arpita Desai
MD
Genitourinary oncologist -
Kelly Fitzgerald
MD
Genitourinary oncologist -
Lawrence H. Fong
MD
Genitourinary oncologist -
Terence W. Friedlander
MD
Genitourinary oncologist -
Vadim S. Koshkin
MD
Genitourinary oncologist -
Akshiv Malhotra
MD
Medical oncologist -
Eric J. Small
MD, FASCO
Genitourinary oncologist
Our locations (1)
Our research initiatives
-
UCSF Prostate Cancer Program Research
The UCSF Prostate Cancer Program conducts research aimed at discovering how prostate cancer develops and progresses, finding the best methods of predicting patient outcomes and developing treatments to improve these outcomes
-
UCSF Helen Diller Family Comprehensive Cancer Center Research
UCSF is home to a range of research initiatives aimed at improving outcomes for cancer patients everywhere. This includes research on topics such as immunotherapy, BRCA mutations and molecular diagnostic testing.
Clinical trials
A Phase 1 Safety and Efficacy Study of IS-002 Injection in Patients Undergoing Robotic Prostatectomy Using the da Vinci® Surgical System With Firefly® Fluorescent Imaging
This is a Phase 1, single-site, interventional clinical trial evaluating the safety and efficacy of IS-002 intravenous (IV) injection for fluorescent identification and delineation of the positive cancer margins and metastatic lymph nodes during prostatectomy surgery using the da Vinci® X/Xi Surgical System with Firefly® Fluorescent Imaging.
Learn moreA Randomized Clinical Trial of Exercise vs. Usual Care Among Men Opting for Active Surveillance for Prostate Cancer
The AS RCT study is a randomized controlled trial of 16-weeks aerobic exercise (home-based walking) vs. usual care among men with prostate cancer on active surveillance.
Learn moreA Randomized Controlled Trial of Diet & Exercise Interventions Among Men With Prostate Cancer - II (Prostate 8-II)
The Prostate 8-II study is a 2-year randomized controlled trial of testing different combinations of educational and supportive tools related to diet and exercise to evaluate biological, clinical, and quality of life outcomes in men choosing radical prostatectomy as treatment for prostate cancer.
Learn moreA Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.
Contact Patricia Li177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
This phase Ib trial studies the dose and schedule of 177Lu-PSMA-617 and pembrolizumab in treating patients with castration-resistant prostate cancer that has spread to other places in the body.
Contact Patricia LiA Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
This study will test the safety and efficacy of FOR46 given every 21 days to patients with metastatic castration-resistant prostate cancer.
Contact Nela PawlowskaNRG- GU 008: Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy
This phase III trial studies how well adding apalutamide, abiraterone acetate, and prednisone to the usual hormone therapy and radiation therapy works compared to the usual hormone therapy and radiation therapy in treating patients with node-positive prostate cancer after surgery.
Learn morePlan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your condition
- List of your medications, including dosages, plus any you're allergic to
- List of questions you may have
- Device or paper for taking notes
